 Home > Food News > Nutrition News > Ionis Pharmaceuticals and AstraZeneca today jointly announced positive results for the scheduled interim analysis of the NEURO-TTRansform Phase 3 trial

Ionis Pharmaceuticals and AstraZeneca today jointly announced positive results for the scheduled interim analysis of the NEURO-TTRansform Phase 3 trial

 Last Update: 2022-09-14
 Source: Internet
 Author: User

Tags

new era cars

pass disa drug test

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Ionis Pharmaceuticals and AstraZeneca today jointly announced positive results

Antisense oligonucleotide (ASO) therapy eplontersen achieved a common primary and secondary endpoint in the treatment of patients with hereditary transthyroxinin (TTR)-mediated amyloidosis multiple neuropathy (ATTRv-PN

Eplontersen is an antisense oligonucleotide drug under investigation that uses the antisense oligonucleotide ligand coupling (LICA) technique to conjugate ASO drugs with ligand molecules that bind to specific receptors on the cell surface

In the interim analysis of the 35-week trial showed that eplontersen resulted in an 81.

Eplontersen caused an 81.

Eplontersen demonstrates good safety and drug resistance

"The eye-catching data from NEURO-TTRansform shows that eplontersen has a positive effect

Resources:

[1] Ionis presents positive results from Phase 3 NEURO-TTRansform study at International Symposium on Amyloidosis.

Disclaimer: WuXi AppTec's content team focuses on the global biomedical health research process

Copyright note: This article is from WuXi AppTec content team, welcome to forward to the circle of friends, refuse the media or institutions to reprint to other platforms

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Factory Provide Citicoline Sodium CAS 33818-15-4 Cdp-Choline Sodium Citicoline Sodium

CAS No.: 33818-15-4

Pharmacy Grade

$100-101/KG FOB

Food Grade Anti Aging CAS 23111-00-4 99% Nicotinamide Riboside Chloride Nrc Nr-Cl Powder

CAS No.: 23111-00-4

Food Grade

$200-201/KG FOB

Cartilage extract

CAS No.:

$75-89/KG FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.